Ibrutinib

Ibrutinib in the glossary for Waldenström's macroglobulinemia

A small molecule inhibitor of Bruton's tyrosine kinase

Ibrutinib is an orally bioavailable, first generation, small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signalling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. Ibrutinib is used to treat patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and Waldenström's macroglobulinemia. Ibrutinib in combination with rituximab was approved in the for the treatment of adults with Waldenström's macroglobulinemia in the EU. ¹ In Australia ibrutinib is approved for use in patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy or as first line in patients with CLL with 17p deletion and patients with mantle cell lymphoma who have received at least one prior therapy.²

Glossary overview

References

1.Ibrutinib SmPC. Available from; https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_en.pdf. Accessed November 12th, 2021.

2.Australian Public Assessment Report for Ibrutinib Available from; https://www.tga.gov.au/auspar/auspar-ibrutinib. Accessed Novemver 12, 2021.

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please consult the appropriate national or regional regulatory authority for specific information on a product or indication included here.